What's new? Log in Free sign up

Chemomab Therapeutics (CMMB) News and press releases

Company Profile

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Why Chemomab Therapeutics Shares Are Trading Higher Today

News, FDA, Movers

Chemomab Therapeutics Ltd (NASDAQ: CMMB) shares are trading higher on Tuesday after the company announced FDA clearance of its Investigational New Drug Application to evaluate CM-101 in a Phase 2 trial in

12 Health Care Stocks Moving In Tuesday's Intraday Session

FDA Gives Green Signal To Chemomab Therapeutics' Rare Disease Study

Biotech, News, Penny Stocks, Health Care, FDA, General

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Chemomab Shares Surge After Positive Data From NASH Biomarker Trial

Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

Chemomab Therapeutics Ltd (NASDAQ: CMMB) reported topline results from its Phase 2a trial assessing CM-101 in non-alcoholic steatohepatitis (NASH) patients.

Wall Street Starts 2023 On Positive Note

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Tuesday.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Chemomab Reports Top-Line Results From CM-101 Phase 2a Liver Fibrosis Biomarker Trial In NASH Patients; Trial Met Primary Endpoint

Biotech, News, FDA, General

TEL AVIV, Israel, Jan. 3, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press releases

From Benzinga Pro

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel, March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

TEL AVIV, Israel, March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for

Thinking about buying stock in Troika Media, AMC Entertainment, Chemomab Therapeutics, DraftKings, or C3.ai?

Opinion, Press Releases

NEW YORK, Feb. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRKA, AMC, CMMB, DKNG, and AI.

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

—ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis— TEL AVIV, Israel, Feb. 21, 2023

Thinking about buying stock in Sorrento Therapeutics, Jasper Therapeutics, Chemomab Therapeutics, ACM Research, or Evaxion Biotech?

Opinion, Press Releases

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, JSPR, CMMB, ACMR, and EVAX.

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments— TEL AVIV, Israel, Jan. 3, 2023 /PRNewswire/ -- Chemomab

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.